Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montirelin SCHEMBL3098148 | 1.00 | TRHR (0.55) | TRHR | |
| Montirelin SCHEMBL7354006 | 1.00 | TRHR (0.55) | TRHR | |
| Montirelin SCHEMBL7311976 | 1.00 | TRHR (0.55) | TRHR | |
| Montirelin SCHEMBL29405744 | 1.00 | TRHR (0.55) | TRHR | |
| Montirelin SCHEMBL3095581 | 0.99 | TRHR (0.54) | TRHR | |
| Montirelin SCHEMBL8498903 | 0.96 | TRHR (0.52) | TRHR | |
| SCHEMBL7318759 | 0.91 | TRHR (0.54) | TRHR | |
| SCHEMBL14028667 | 0.90 | TRHR (0.43) | TRHR | |
| SCHEMBL7310894 | 0.89 | TRHR (0.52) | TRHR | |
| SCHEMBL8257280 | 0.89 | TRHR (0.42) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462595-B2 | Methods for treating cancer-related fatigue | TRH THERAPEUTICS LLC | 2008-12-09 | — | — | US | disclosed |
| US-20080249028-A1 | Thyrotropin-Releasing Hormone Analogs and Method of Use | ROGER WILLIAMS HOSPITAL (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1793842-A2 | TREATMENT FOR CANCER-RELATED FATIGUE | Winokur, Andrew (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060063703-A1 | Methods for treating cancer-related fatigue | TRH THERAPEUTICS LLC | 2006-03-23 | — | — | US | disclosed |
| WO-2006031980-A2 | TREATMENT FOR CANCER-RELATED FATIGUE | WINOKUR ANDREW (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249028-A1 | Thyrotropin-Releasing Hormone Analogs and Method of Use | TRHR, IAPP, TRHDE | TRHR 1/4885 |
| US-20060063703-A1 | Methods for treating cancer-related fatigue | CRH, TRHR, SSTR4 | TRHR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.